Compare iShares MSCI Germany (DAX) (EWG) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Germany (DAX) vs Novo Nordisk A/S — how do they compare? iShares MSCI Germany (DAX) trades at $41.2, while Novo Nordisk A/S trades at $51.62 (market cap $222.24B). The key difference: Novo Nordisk A/S pays a 3.56% dividend while iShares MSCI Germany (DAX) pays none. Which is the better fit depends on your goals.
| EWG | NVO | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $44.56 | $71.70 |
52-Week Low | $38.08 | $35.29 |
Market Cap | — | $222.24B |
Enterprise Value | — | $241.20B |
Dividend Yield | — | 3.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWG trades at $41.10, down 0.7% on the day, with a neutral technical signal and bearish moving averages. Key support is at $41 and resistance at $42. The stock lacks available financial ratios, and a dividend of $0.83 is scheduled for June 2026. Recent news highlights German economic policies and ECB rate decisions influencing European market sentiment.
The outlook is cautious due to limited fundamental data and mixed technical indicators. Risks include macroeconomic volatility from energy prices and ECB policy shifts. Analyst sentiment is neutral, with no clear consensus on price targets or ratings available.
Novo Nordisk (NVO) trades at $51.52, up 4.99% in the last session, with strong technical momentum and bullish moving averages. The company maintains robust fundamentals, including a 37.2% net income margin and consistent earnings beats in recent quarters. Recent EU approval for the Wegovy weight-loss pill (Reuters, 2026-07-15) reinforces its leadership in GLP-1 therapies, though competition is intensifying.
Outlook remains positive given solid cash flow growth and analyst support, but risks include pricing pressure from generics and slowing prescription trends. The stock's valuation at a P/E of 12.14 offers relative value in the pharma sector, with upside potential if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Germany (DAX)
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
